最新ニュース Humana (NYSE:HUM) 株価情報

HUMANA INC

Humana

Humana is one of the largest private health insurers in the US, and the firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from Medicare, Medicaid, and the military's Tricare program. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.

Earnings

News

Guidance

Health Care

Movers

General

水曜日、Humana Inc (NYSE:HUM) は、1株あたり6.96ドルの調整後EPSを報告し、これは1年前の1株あたり8.94ドルから減少しており、5.85ドルのコンセンサスを上回る結果となった。

保険大手ヒュマナの株価が下落　調整後FPS報告を受けて

Humana Inc

Humanscape

Humacyte Inc

Humble & Fume Inc

Hua Medicine

Humm Group Ltd

Humble Energy Inc

Hummingbird Resources PLC

Humatech Inc

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders often look for circumstances when the market estimation of an option diverges away from its normal worth. Abnormal amounts of trading activity could push option prices to hyperbolic or underperforming levels. 
Here's the list of options activity happening in today's session: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>IRON</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>04/17/25</td>
<td>$50.00</td>
<td>$160.0K</td>
<td>4</td>
<td>2.0K</td>
</tr>
<tr>
<td>VRNA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>05/16/25</td>
<td>$70.00</td>
<td>$55.4K</td>
<td>372</td>
<td>500</td>
</tr>
<tr>
<td>MRNA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$25.00</td>
<td>$28.3K</td>
<td>6.7K</td>
<td>302</td>
</tr>
<tr>
<td>HUM</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>04/17/25</td>
<td>$310.00</td>
<td>$25.5K</td>
<td>8.7K</td>
<td>173</td>
</tr>
<tr>
<td>AKRO</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>04/17/25</td>
<td>$40.00</td>
<td>$25.8K</td>
<td>0</td>
<td>150</td>
</tr>
<tr>
<td>HIMS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>07/18/25</td>
<td>$37.00</td>
<td>$47.8K</td>
<td>839</td>
<td>114</td>
</tr>
<tr>
<td>LLY</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>05/16/25</td>
<td>$690.00</td>
<td>$37.0K</td>
<td>212</td>
<td>33</td>
</tr>
<tr>
<td>NVO</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$77.50</td>
<td>$36.0K</td>
<td>1.4K</td>
<td>26</td>
</tr>
<tr>
<td>TMO</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>05/16/25</td>
<td>$470.00</td>
<td>$32.8K</td>
<td>2</td>
<td>11</td>
</tr>
<tr>
<td>MCK</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/15/27</td>
<td>$680.00</td>
<td>$124.6K</td>
<td>10</td>
<td>11</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These bullet-by-bullet explanations have been constructed using the accompanying table. 
• Regarding IRON (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRON#NASDAQ">IRON</a>), we observe a call option trade with bearish sentiment. It expires in 16 day(s) on April 17, 2025. Parties traded 2000 contract(s) at a $50.00 strike. The total cost received by the writing party (or parties) was $160.0K, with a price of $80.0 per contract. There were 4 open contracts at this strike prior to today, and today 2000 contract(s) were bought and sold. 
• For VRNA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRNA#NASDAQ">VRNA</a>), we notice a call option sweep that happens to be bearish, expiring in 45 day(s) on May 16, 2025. This event was a transfer of 241 contract(s) at a $70.00 strike. This particular call needed to be split into 19 different trades to become filled. The total cost received by the writing party (or parties) was $55.4K, with a price of $230.0 per contract. There were 372 open contracts at this strike prior to today, and today 500 contract(s) were bought and sold. 
• For MRNA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>), we notice a put option sweep that happens to be bearish, expiring in 290 day(s) on January 16, 2026. This event was a transfer of 59 contract(s) at a $25.00 strike. This particular put needed to be split into 12 different trades to become filled. The total cost received by the writing party (or parties) was $28.3K, with a price of $480.0 per contract. There were 6708 open contracts at this strike prior to today, and today 302 contract(s) were bought and sold. 
• Regarding HUM (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>), we observe a call option trade with bearish sentiment. It expires in 16 day(s) on April 17, 2025. Parties traded 37 contract(s) at a $310.00 strike. The total cost received by the writing party (or parties) was $25.5K, with a price of $690.0 per contract. There were 8768 open contracts at this strike prior to today, and today 173 contract(s) were bought and sold. 
• For AKRO (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKRO#NASDAQ">AKRO</a>), we notice a call option sweep that happens to be bullish, expiring in 16 day(s) on April 17, 2025. This event was a transfer of 150 contract(s) at a $40.00 strike. This particular call needed to be split into 5 different trades to become filled. The total cost received by the writing party (or parties) was $25.8K, with a price of $170.0 per contract. There were 0 open contracts at this strike prior to today, and today 150 contract(s) were bought and sold. 
• For HIMS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>), we notice a call option sweep that happens to be bearish, expiring in 108 day(s) on July 18, 2025. This event was a transfer of 90 contract(s) at a $37.00 strike. This particular call needed to be split into 5 different trades to become filled. The total cost received by the writing party (or parties) was $47.8K, with a price of $532.0 per contract. There were 839 open contracts at this strike prior to today, and today 114 contract(s) were bought and sold. 
• Regarding LLY (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), we observe a put option trade with bullish sentiment. It expires in 45 day(s) on May 16, 2025. Parties traded 30 contract(s) at a $690.00 strike. The total cost received by the writing party (or parties) was $37.0K, with a price of $1236.0 per contract. There were 212 open contracts at this strike prior to today, and today 33 contract(s) were bought and sold. 
• Regarding NVO (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>), we observe a put option trade with bearish sentiment. It expires in 290 day(s) on January 16, 2026. Parties traded 24 contract(s) at a $77.50 strike. The total cost received by the writing party (or parties) was $36.0K, with a price of $1500.0 per contract. There were 1454 open contracts at this strike prior to today, and today 26 contract(s) were bought and sold. 
• For TMO (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>), we notice a call option trade that happens to be bearish, expiring in 45 day(s) on May 16, 2025. This event was a transfer of 10 contract(s) at a $470.00 strike. The total cost received by the writing party (or parties) was $32.8K, with a price of $3280.0 per contract. There were 2 open contracts at this strike prior to today, and today 11 contract(s) were bought and sold. 
• Regarding MCK (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCK#NYSE">MCK</a>), we observe a call option trade with bearish sentiment. It expires in 654 day(s) on January 15, 2027. Parties traded 11 contract(s) at a $680.00 strike. The total cost received by the writing party (or parties) was $124.6K, with a price of $11330.0 per contract. There were 10 open contracts at this strike prior to today, and today 11 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more about unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Options

AKRO

Hims & Hers Health, Inc. Class A Common Stock

HIMS

IRON

MRNA

VRNA

10 Health Care Stocks With Whale Alerts In Today's Session

Deep-pocketed investors have adopted a bearish approach towards Humana (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in HUM usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 17 extraordinary options activities for Humana. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 29% leaning bullish and 47% bearish. Among these notable options, 11 are puts, totaling $1,294,783, and 6 are calls, amounting to $257,816.
<h3>Predicted Price Range</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $195.0 to $350.0 for Humana over the recent three months. 
<h3>Insights into Volume &amp; Open Interest</h3>
In terms of liquidity and interest, the mean open interest for Humana options trades today is 621.09 with a total volume of 1,733.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for Humana's big money trades within a strike price range of $195.0 to $350.0 over the last 30 days.
<h3>Humana Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1742235370_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>HUM</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>03/28/25</td>
<td>$9.6</td>
<td>$8.1</td>
<td>$8.75</td>
<td>$255.00</td>
<td>$437.5K</td>
<td align="right">59</td>
<td align="right">507</td>
</tr>
<tr>
<td>HUM</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$37.1</td>
<td>$36.6</td>
<td>$36.98</td>
<td>$280.00</td>
<td>$287.2K</td>
<td align="right">229</td>
<td align="right">203</td>
</tr>
<tr>
<td>HUM</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$37.0</td>
<td>$36.7</td>
<td>$36.88</td>
<td>$280.00</td>
<td>$162.4K</td>
<td align="right">229</td>
<td align="right">105</td>
</tr>
<tr>
<td>HUM</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>04/17/25</td>
<td>$23.0</td>
<td>$22.5</td>
<td>$22.5</td>
<td>$260.00</td>
<td>$65.2K</td>
<td align="right">706</td>
<td align="right">29</td>
</tr>
<tr>
<td>HUM</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>06/20/25</td>
<td>$38.0</td>
<td>$37.6</td>
<td>$37.8</td>
<td>$280.00</td>
<td>$60.4K</td>
<td align="right">229</td>
<td align="right">25</td>
</tr>
</tbody>
</table>

<h3>About Humana</h3>
Humana is one of the largest private health insurers in the US, and the firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from individual and group Medicare Advantage, Medicaid, and the military's Tricare program. The firm is also a leader in stand-alone prescription drug plans for seniors enrolled in traditional fee-for-service Medicare. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.
<h3>Current Position of Humana</h3>
<ul>
<li>Currently trading with a volume of 481,880, the HUM's price is down by 0.0%, now at $252.88. </li>
<li>RSI readings suggest the stock is currently may be approaching overbought.</li>
<li>Anticipated earnings release is in 37 days.</li>
</ul>
<h3>Expert Opinions on Humana</h3>
Over the past month, 1 industry analysts have shared their insights on this stock, proposing an average target price of $256.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; Consistent in their evaluation, an analyst from JP Morgan keeps a Neutral rating on Humana with a target price of $256. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Humana, <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> gives you real-time options trades alerts.

Markets

Spotlight on Humana: Analyzing the Surge in Options Activity

Humana's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>) short percent of float has fallen 6.3% since its last report. The company recently reported that it has 4.30 million shares sold short, which is 3.57% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.04 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Humana Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1741353321_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Humana has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Humana's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Humana's peer group average for short interest as a percentage of float is 5.13%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Trading Ideas

Peering Into Humana's Recent Short Interest

Humana announced that it has priced a public offering of $1.25 billion in aggregate principal amount of senior notes. These senior notes are comprised of $750 million of the company's 5.550 percent senior notes, due 2035, at 99.885 percent of the principal amount and $500 million of the company's 6.000 percent senior notes, due 2055, at 98.951 percent of the principal amount (collectively, the "Senior Notes Offerings"). The Senior Notes Offerings are expected to close on March 5, 2025, subject to the satisfaction of customary closing conditions.

Reported Earlier, Humana Prices $1.25B Debt Offering, Including $750M 5.550% Senior Notes Due 2035 And $500M 6.000% Senior Notes Due 2055

Humana Intends To Reaffirm Its FY25 Adjusted EPS Guidance Of Approximately $16.25, Est $16.69

Investors with a lot of money to spend have taken a bullish stance on Humana (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with HUM, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://www.benzinga.com/pro/">Benzinga</a>'s options scanner spotted 8 uncommon options trades for Humana.
This isn't normal.
The overall sentiment of these big-money traders is split between 50% bullish and 25%, bearish.
Out of all of the special options we uncovered, 3 are puts, for a total amount of $127,080, and 5 are calls, for a total amount of $707,764.
<h3>Projected Price Targets</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $205.0 to $360.0 for Humana over the recent three months. 
<h3>Volume &amp; Open Interest Development</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for Humana's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Humana's whale activity within a strike price range from $205.0 to $360.0 in the last 30 days. 
<h3>Humana Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1740762971_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>HUM</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>09/19/25</td>
<td>$10.9</td>
<td>$10.1</td>
<td>$10.9</td>
<td>$360.00</td>
<td>$545.0K</td>
<td>36</td>
<td align="right">502</td>
</tr>
<tr>
<td>HUM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>04/17/25</td>
<td>$16.7</td>
<td>$16.3</td>
<td>$16.3</td>
<td>$280.00</td>
<td>$65.2K</td>
<td>2.8K</td>
<td align="right">0</td>
</tr>
<tr>
<td>HUM</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$21.8</td>
<td>$21.1</td>
<td>$21.2</td>
<td>$230.00</td>
<td>$53.0K</td>
<td>244</td>
<td align="right">25</td>
</tr>
<tr>
<td>HUM</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$21.8</td>
<td>$21.1</td>
<td>$21.2</td>
<td>$230.00</td>
<td>$40.2K</td>
<td>244</td>
<td align="right">44</td>
</tr>
<tr>
<td>HUM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>04/17/25</td>
<td>$12.0</td>
<td>$11.5</td>
<td>$11.5</td>
<td>$300.00</td>
<td>$39.1K</td>
<td>722</td>
<td align="right">48</td>
</tr>
</tbody>
</table>

<h3>About Humana</h3>
Humana is one of the largest private health insurers in the US, and the firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from individual and group Medicare Advantage, Medicaid, and the military's Tricare program. The firm is also a leader in stand-alone prescription drug plans for seniors enrolled in traditional fee-for-service Medicare. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.
Having examined the options trading patterns of Humana, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
<h3>Current Position of Humana</h3>
<ul>
<li>With a volume of 320,736, the price of HUM is up 2.68% at $268.45. </li>
<li>RSI indicators hint that the underlying stock is currently neutral between overbought and oversold.</li>
<li>Next earnings are expected to be released in 54 days.</li>
</ul>
<h3>Expert Opinions on Humana</h3>
Over the past month, 5 industry analysts have shared their insights on this stock, proposing an average target price of $276.8.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; An analyst from Morgan Stanley persists with their Equal-Weight rating on Humana, maintaining a target price of $285. 
&#x2A; An analyst from JP Morgan persists with their Neutral rating on Humana, maintaining a target price of $256. 
&#x2A; Reflecting concerns, an analyst from Cantor Fitzgerald lowers its rating to Neutral with a new price target of $290. 
&#x2A; In a cautious move, an analyst from RBC Capital downgraded its rating to Outperform, setting a price target of $283. 
&#x2A; Maintaining their stance, an analyst from Barclays continues to hold a Equal-Weight rating for Humana, targeting a price of $270. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Humana options trades with real-time alerts from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.

Behind the Scenes of Humana's Latest Options Trends

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders often look for circumstances when the market estimation of an option diverges away from its normal worth. Abnormal amounts of trading activity could push option prices to hyperbolic or underperforming levels. 
Below are some instances of options activity happening in the Health Care sector: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>HIMS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>04/17/25</td>
<td>$48.00</td>
<td>$81.9K</td>
<td>541</td>
<td align="right">474</td>
</tr>
<tr>
<td>MDGL</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>04/17/25</td>
<td>$380.00</td>
<td>$74.5K</td>
<td>42</td>
<td align="right">88</td>
</tr>
<tr>
<td>AMGN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>02/28/25</td>
<td>$295.00</td>
<td>$34.6K</td>
<td>148</td>
<td align="right">31</td>
</tr>
<tr>
<td>TGTX</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/16/26</td>
<td>$20.00</td>
<td>$26.3K</td>
<td>2.6K</td>
<td align="right">26</td>
</tr>
<tr>
<td>SRPT</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>05/16/25</td>
<td>$110.00</td>
<td>$25.4K</td>
<td>86</td>
<td align="right">25</td>
</tr>
<tr>
<td>VRTX</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>02/28/25</td>
<td>$300.00</td>
<td>$91.7K</td>
<td>3</td>
<td align="right">15</td>
</tr>
<tr>
<td>LLY</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$960.00</td>
<td>$120.4K</td>
<td>79</td>
<td align="right">10</td>
</tr>
<tr>
<td>UNH</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$480.00</td>
<td>$27.2K</td>
<td>1.1K</td>
<td align="right">9</td>
</tr>
<tr>
<td>HUM</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>03/20/26</td>
<td>$280.00</td>
<td>$32.2K</td>
<td>2</td>
<td align="right">6</td>
</tr>
<tr>
<td>MCK</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$590.00</td>
<td>$26.2K</td>
<td>7</td>
<td align="right">0</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These itemized elaborations have been created using the accompanying table. 
• Regarding HIMS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>), we observe a call option sweep with neutral sentiment. It expires in 50 day(s) on April 17, 2025. Parties traded 200 contract(s) at a $48.00 strike. This particular call needed to be split into 3 different trades to become filled. The total cost received by the writing party (or parties) was $81.9K, with a price of $410.0 per contract. There were 541 open contracts at this strike prior to today, and today 474 contract(s) were bought and sold. 
• For MDGL (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDGL#NASDAQ">MDGL</a>), we notice a call option sweep that happens to be bearish, expiring in 50 day(s) on April 17, 2025. This event was a transfer of 25 contract(s) at a $380.00 strike. This particular call needed to be split into 3 different trades to become filled. The total cost received by the writing party (or parties) was $74.5K, with a price of $2970.0 per contract. There were 42 open contracts at this strike prior to today, and today 88 contract(s) were bought and sold. 
• For AMGN (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>), we notice a call option sweep that happens to be neutral, expiring in 2 day(s) on February 28, 2025. This event was a transfer of 25 contract(s) at a $295.00 strike. This particular call needed to be split into 6 different trades to become filled. The total cost received by the writing party (or parties) was $34.6K, with a price of $1387.0 per contract. There were 148 open contracts at this strike prior to today, and today 31 contract(s) were bought and sold. 
• For TGTX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TGTX#NASDAQ">TGTX</a>), we notice a call option trade that happens to be neutral, expiring in 324 day(s) on January 16, 2026. This event was a transfer of 20 contract(s) at a $20.00 strike. The total cost received by the writing party (or parties) was $26.3K, with a price of $1315.0 per contract. There were 2612 open contracts at this strike prior to today, and today 26 contract(s) were bought and sold. 
• Regarding SRPT (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>), we observe a call option trade with neutral sentiment. It expires in 79 day(s) on May 16, 2025. Parties traded 25 contract(s) at a $110.00 strike. The total cost received by the writing party (or parties) was $25.4K, with a price of $1020.0 per contract. There were 86 open contracts at this strike prior to today, and today 25 contract(s) were bought and sold. 
• Regarding VRTX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>), we observe a call option trade with neutral sentiment. It expires in 2 day(s) on February 28, 2025. Parties traded 5 contract(s) at a $300.00 strike. The total cost received by the writing party (or parties) was $91.7K, with a price of $18346.0 per contract. There were 3 open contracts at this strike prior to today, and today 15 contract(s) were bought and sold. 
• Regarding LLY (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), we observe a put option trade with bearish sentiment. It expires in 324 day(s) on January 16, 2026. Parties traded 10 contract(s) at a $960.00 strike. The total cost received by the writing party (or parties) was $120.4K, with a price of $12040.0 per contract. There were 79 open contracts at this strike prior to today, and today 10 contract(s) were bought and sold. 
• Regarding UNH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>), we observe a put option sweep with bullish sentiment. It expires in 324 day(s) on January 16, 2026. Parties traded 5 contract(s) at a $480.00 strike. This particular put needed to be split into 5 different trades to become filled. The total cost received by the writing party (or parties) was $27.2K, with a price of $5455.0 per contract. There were 1141 open contracts at this strike prior to today, and today 9 contract(s) were bought and sold. 
• Regarding HUM (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>), we observe a put option sweep with bearish sentiment. It expires in 387 day(s) on March 20, 2026. Parties traded 6 contract(s) at a $280.00 strike. This particular put needed to be split into 5 different trades to become filled. The total cost received by the writing party (or parties) was $32.2K, with a price of $5383.0 per contract. There were 2 open contracts at this strike prior to today, and today 6 contract(s) were bought and sold. 
• For MCK (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCK#NYSE">MCK</a>), we notice a put option trade that happens to be bullish, expiring in 688 day(s) on January 15, 2027. This event was a transfer of 5 contract(s) at a $590.00 strike. The total cost received by the writing party (or parties) was $26.2K, with a price of $5258.0 per contract. There were 7 open contracts at this strike prior to today, and today 0 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more news on unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AMGN

MDGL

SRPT

TGTX

VRTX

10 Health Care Stocks Whale Activity In Today's Session

Humana Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>), a leading health and well-being company, today introduced a new value-based care agreement with Thyme Care to provide comprehensive cancer care support for eligible Humana Medicare Advantage members. Value-based care is a holistic, patient-centered model designed to improve patient health outcomes and quality of life while helping to make healthcare more affordable and accessible.Cancer is the second-leading cause of death in the United States, with devastating physical, emotional, and financial consequences. Humana's collaboration with Thyme Care is designed to address these challenges through 24/7 virtual care navigation, data-driven insights that empower Care Teams to intervene early, and provider-led pharmacy interventions that reduce patient out-of-pocket costs. This proactive approach to cancer care minimizes care gaps, reduces costly and unnecessary expenditures, and supports patients while managing the complexities and costs of cancer care. "Receiving a cancer diagnosis is a pivotal moment that requires the right care and support," said Humana Medical Director Dr. Bryan Loy. "As a leader in value-based care, we are excited to team up with Thyme Care to ensure our members have access to comprehensive, high-touch oncology services." Humana Medicare Advantage members who are eligible for the program in Michigan, New York, Illinois, Indiana, Tennessee, Pennsylvania, and New Jersey now have access to Thyme Care's suite of services. This includes: &nbsp;
<ul>
<li>24/7 virtual care navigation: Thyme Care's dedicated Care Team, comprised of oncology nurses, nurse practitioners, social workers, and resource specialists, provides clinical and non-clinical support in between appointments, including medication guidance and symptom management, urgent care support, chronic condition management, and access to palliative care support.</li>
<li>Community support beyond the clinic: a localized team proactively identifies needs and connects members to community-based resources, including financial assistance, transportation to and from their appointments, food assistance, or access to stable housing.</li>
<li>Care coordination between providers: Thyme Care coordinates seamlessly with a member's oncologist, primary care physician, and other specialists to ensure everyone has the right information at the right time to make informed care decisions.</li>
</ul>

Biotech

Humana Announces Partnership With Thyme Care To Offer Comprehensive Cancer Support To Medicare Advantage Members In Seven States, Featuring 24/7 Virtual Care, Data-Driven Early Intervention, And Pharmacy Interventions

WIIM

streetTRACKS Dow Jones U.S. Large Cap Value Index Fund

Shares of health insurers are trading lower. Weakness in the sector may be in sympathy with UnitedHealth, which fell on reports of a DOJ investigation into Medicare billing practices.

JP Morgan analyst Lisa Gill maintains Humana (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>) with a Neutral and lowers the price target from $257 to $256.

Price Target

Analyst Ratings

JP Morgan Maintains Neutral on Humana, Lowers Price Target to $256

Humana's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>) short percent of float has fallen 11.4% since its last report. The company recently reported that it has 4.58 million shares sold short, which is 3.81% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.71 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Humana Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1739802617_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Humana has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Humana's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Humana's peer group average for short interest as a percentage of float is 4.87%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Looking Into Humana's Recent Short Interest

Deep-pocketed investors have adopted a bullish approach towards Humana (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in HUM usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 16 extraordinary options activities for Humana. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 75% leaning bullish and 18% bearish. Among these notable options, 14 are puts, totaling $579,028, and 2 are calls, amounting to $283,180.
<h3>Expected Price Movements</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $230.0 to $320.0 for Humana over the recent three months. 
<h3>Analyzing Volume &amp; Open Interest</h3>
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Humana's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Humana's substantial trades, within a strike price spectrum from $230.0 to $320.0 over the preceding 30 days.
<h3>Humana Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1739466037_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>HUM</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>02/28/25</td>
<td>$7.9</td>
<td>$6.6</td>
<td>$7.9</td>
<td>$260.00</td>
<td>$197.5K</td>
<td align="right">69</td>
<td align="right">250</td>
</tr>
<tr>
<td>HUM</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$48.9</td>
<td>$47.6</td>
<td>$47.6</td>
<td>$250.00</td>
<td>$85.6K</td>
<td align="right">448</td>
<td align="right">18</td>
</tr>
<tr>
<td>HUM</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$6.9</td>
<td>$6.4</td>
<td>$6.8</td>
<td>$257.50</td>
<td>$83.6K</td>
<td align="right">86</td>
<td align="right">125</td>
</tr>
<tr>
<td>HUM</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$22.8</td>
<td>$22.5</td>
<td>$22.5</td>
<td>$250.00</td>
<td>$49.5K</td>
<td align="right">131</td>
<td align="right">22</td>
</tr>
<tr>
<td>HUM</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$26.0</td>
<td>$22.5</td>
<td>$22.7</td>
<td>$250.00</td>
<td>$45.4K</td>
<td align="right">131</td>
<td align="right">179</td>
</tr>
</tbody>
</table>

<h3>About Humana</h3>
Humana is one of the largest private health insurers in the us with a focus on administering Medicare Advantage plans. The firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from individual and group Medicare Advantage, Medicaid, and the military's Tricare program. The firm is also a leader in stand-alone prescription drug plans for seniors enrolled in traditional fee-for-service Medicare. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.
After a thorough review of the options trading surrounding Humana, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Present Market Standing of Humana</h3>
<ul>
<li>Trading volume stands at 334,823, with HUM's price down by -1.33%, positioned at $256.57.</li>
<li>RSI indicators show the stock to be may be approaching oversold.</li>
<li>Earnings announcement expected in 69 days.</li>
</ul>
<h3>What Analysts Are Saying About Humana</h3>
A total of 5 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $277.2.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Consistent in their evaluation, an analyst from Piper Sandler keeps a Neutral rating on Humana with a target price of $288. 
&#x2A; Reflecting concerns, an analyst from RBC Capital lowers its rating to Outperform with a new price target of $283. 
&#x2A; Consistent in their evaluation, an analyst from Barclays keeps a Equal-Weight rating on Humana with a target price of $270. 
&#x2A; An analyst from Cantor Fitzgerald downgraded its action to Neutral with a price target of $290. 
&#x2A; An analyst from Barclays persists with their Equal-Weight rating on Humana, maintaining a target price of $255. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Humana, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

Check Out What Whales Are Doing With HUM

Barclays analyst Andrew Mok maintains Humana (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>) with a Equal-Weight and raises the price target from $255 to $270.

Barclays Maintains Equal-Weight on Humana, Raises Price Target to $270

Humana and Monogram Health are pleased to announce a significant expansion, extending member access to in-home treatment for kidney disease and its underlying causes. Eligible Humana Medicare Advantage members in Alabama, Louisiana, Mississippi, Tennessee, and now Georgia with chronic kidney disease (CKD) and end-stage kidney disease (ESKD) will have access to Monogram's evidence-based nephrology and multispecialty value-based care in the comfort of their homes.

Humana And Monogram Health Announce Expansion To Provide In-Home Kidney Care For Medicare Advantage Members In Alabama, Louisiana, Mississippi, Tennessee, And Georgia

On Tuesday, Humana Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>) posted a fourth-quarter adjusted earnings per share loss of $2.16. That&#8217;s down from 11 cents a year ago, <a href="https://www.benzinga.com/earnings" target="_blank" rel="noreferrer noopener">in line with the consensus</a> and including <a href="https://www.benzinga.com/government/regulations/25/01/43173248/us-health-agency-cms-to-appeal-medicare-star-ratings-recalculation-ruling" target="_blank" rel="noreferrer noopener">incremental investments in Stars</a>.
The company reported revenues of $29.19 billion, up 13.5% year-over-year from $25.73 billion, beating the&nbsp;<a target="_blank" href="https://www.benzinga.com/25/02/43621782/insurance-giant-humanas-q4-earnings-at-par-with-estimates-2025-profit-outlook-falls-below-street-view" rel="noreferrer noopener">consensus of $28.84 billion</a>.
For 2025, Humana expects its insurance segment's benefit ratio guidance of approximately 90.1-90.5%.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/health-care/25/01/43321236/rfk-jr-and-big-pharma-stocks-to-watch-as-health-secretary-hopeful-answers-pointed-questions-on-drugs-insurance-trump-exec-orders" rel="noreferrer noopener">RFK Jr. And Big Pharma: Health Secretary Hopeful Answers Pointed Questions On Drugs, Insurance, Trump Exec Orders</a>
Cantor Fitzgerald expects a more cautious approach to cost trend assumptions. However, analysts Sarah James and Gabie Ingoglia acknowledge the reasoning behind expecting some moderation.
&#8220;We have incremental concerns over outlier assumptions on cost trends though find some logic in the rationale, and we believe the Street may be underestimating the earnings power in turning around the group MA book in &#8217;26 and &#8217;27, which we estimate could represent a $1-2 earnings drag to 2025,&#8221; the analysts wrote.
Humana stands out by projecting a slowdown in the 2025 cost trend to the mid-single digits compared to the high-single digits in 2024. This contrasts with UnitedHealth Group Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>), Elevance Health Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELV#NYSE">ELV</a>), and Molina Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>), which anticipate continued elevated trends from 2024.
Humana attributes the expected slowdown to factors that won't repeat in 2025, such as the impact of the &#8220;two-midnight&#8221; rule, though it still expects high specialty drug costs. The company also noted stable cost trends from Q3 to Q4 2024, except for seasonal increases in supplemental benefits that drive year-end utilization.
Management plans to aggressively cut costs and AEP results confirm the company&#8217;s pricing strategy is working, analysts say. However, the company lost about 30,000 D-SNP members due to redetermination.
Another positive is that the PDP pricing strategy isn't facing issues.
Price Action: Humana stock is up 0.80% at $259.40 at last check Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/25/02/43662901/why-is-nano-cap-cancer-focused-xilio-therapeutics-stock-trading-over-100-on-wednesday" target="_blank" rel="noreferrer noopener">Why Is Nano-Cap Cancer-Focused Xilio Therapeutics Stock Trading Over 100% On Wednesday?</a></li>
</ul>
Image: Shutterstock

Analyst Color

Earnings Beats

Large Cap

Humana 2025 Outlook Shows Cautious Optimism Despite Industry Pressures

In the last three months, 7 analysts have published ratings on Humana (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>), offering a diverse range of perspectives from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">6</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $284.57, a high estimate of $301.00, and a low estimate of $255.00. Observing a 2.41% increase, the current average has risen from the previous average price target of $277.86. 
<img src="https://www.benzinga.com/files/images/story/2025/1739383265_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Humana. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ben Hendrix</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$283.00</td>
<td>$283.00</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$290.00</td>
<td>$290.00</td>
</tr>
<tr>
<td>Erin Wright</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$285.00</td>
<td>$301.00</td>
</tr>
<tr>
<td>Andrew Mok</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$255.00</td>
<td>$253.00</td>
</tr>
<tr>
<td>Jessica Tassan</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Neutral</td>
<td>$288.00</td>
<td>$270.00</td>
</tr>
<tr>
<td>David Macdonald</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$290.00</td>
<td>$260.00</td>
</tr>
<tr>
<td>Erin Wright</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$301.00</td>
<td>$288.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Humana. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Humana compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Humana's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Humana's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/HUM/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Humana analyst ratings.</a>
<h2>About Humana</h2>
Humana is one of the largest private health insurers in the us with a focus on administering Medicare Advantage plans. The firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from individual and group Medicare Advantage, Medicaid, and the military's Tricare program. The firm is also a leader in stand-alone prescription drug plans for seniors enrolled in traditional fee-for-service Medicare. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.
<h3>Humana: Financial Performance Dissected</h3>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Positive Revenue Trend: Examining Humana's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 11.26% as of 30 September, 2024, showcasing a substantial increase in top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Humana's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 1.63% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Humana's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 2.8% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Humana's ROA stands out, surpassing industry averages. With an impressive ROA of 0.96%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: Humana's debt-to-equity ratio stands notably higher than the industry average, reaching 0.74. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
<h2>Analyst Ratings: What Are They?</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Deep Dive Into Humana Stock: Analyst Perspectives (7 Ratings)

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders often look for circumstances when the market estimation of an option diverges away from its normal worth. Abnormal amounts of trading activity could push option prices to hyperbolic or underperforming levels. 
Here's the list of options activity happening in today's session: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>PFE</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$27.50</td>
<td>$48.6K</td>
<td>44.4K</td>
<td>7.2K</td>
</tr>
<tr>
<td>ACAD</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$20.00</td>
<td>$157.6K</td>
<td>109</td>
<td>1.9K</td>
</tr>
<tr>
<td>TEM</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>04/17/25</td>
<td>$65.00</td>
<td>$28.5K</td>
<td>2.8K</td>
<td>840</td>
</tr>
<tr>
<td>ZTS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$180.00</td>
<td>$43.0K</td>
<td>1.4K</td>
<td>316</td>
</tr>
<tr>
<td>EBS</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$11.00</td>
<td>$43.8K</td>
<td>4</td>
<td>200</td>
</tr>
<tr>
<td>BMRN</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$65.00</td>
<td>$29.2K</td>
<td>1.3K</td>
<td>159</td>
</tr>
<tr>
<td>HUM</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>04/17/25</td>
<td>$245.00</td>
<td>$191.7K</td>
<td>141</td>
<td>125</td>
</tr>
<tr>
<td>HIMS</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$37.00</td>
<td>$69.7K</td>
<td>1.0K</td>
<td>87</td>
</tr>
<tr>
<td>EXEL</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>02/21/25</td>
<td>$17.00</td>
<td>$29.5K</td>
<td>98</td>
<td>50</td>
</tr>
<tr>
<td>LLY</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$800.00</td>
<td>$37.5K</td>
<td>843</td>
<td>31</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These bullet-by-bullet explanations have been constructed using the accompanying table. 
• For PFE (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>), we notice a call option sweep that happens to be bullish, expiring in 37 day(s) on March 21, 2025. This event was a transfer of 2561 contract(s) at a $27.50 strike. This particular call needed to be split into 21 different trades to become filled. The total cost received by the writing party (or parties) was $48.6K, with a price of $19.0 per contract. There were 44426 open contracts at this strike prior to today, and today 7236 contract(s) were bought and sold. 
• For ACAD (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACAD#NASDAQ">ACAD</a>), we notice a call option sweep that happens to be bullish, expiring in 128 day(s) on June 20, 2025. This event was a transfer of 901 contract(s) at a $20.00 strike. This particular call needed to be split into 8 different trades to become filled. The total cost received by the writing party (or parties) was $157.6K, with a price of $175.0 per contract. There were 109 open contracts at this strike prior to today, and today 1920 contract(s) were bought and sold. 
• For TEM (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEM#NASDAQ">TEM</a>), we notice a call option trade that happens to be bearish, expiring in 64 day(s) on April 17, 2025. This event was a transfer of 20 contract(s) at a $65.00 strike. The total cost received by the writing party (or parties) was $28.5K, with a price of $1425.0 per contract. There were 2849 open contracts at this strike prior to today, and today 840 contract(s) were bought and sold. 
• For ZTS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZTS#NYSE">ZTS</a>), we notice a call option sweep that happens to be bearish, expiring in 9 day(s) on February 21, 2025. This event was a transfer of 200 contract(s) at a $180.00 strike. This particular call needed to be split into 6 different trades to become filled. The total cost received by the writing party (or parties) was $43.0K, with a price of $215.0 per contract. There were 1473 open contracts at this strike prior to today, and today 316 contract(s) were bought and sold. 
• Regarding EBS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EBS#NYSE">EBS</a>), we observe a call option trade with bearish sentiment. It expires in 219 day(s) on September 19, 2025. Parties traded 200 contract(s) at a $11.00 strike. The total cost received by the writing party (or parties) was $43.8K, with a price of $219.0 per contract. There were 4 open contracts at this strike prior to today, and today 200 contract(s) were bought and sold. 
• Regarding BMRN (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMRN#NASDAQ">BMRN</a>), we observe a call option trade with bullish sentiment. It expires in 9 day(s) on February 21, 2025. Parties traded 150 contract(s) at a $65.00 strike. The total cost received by the writing party (or parties) was $29.2K, with a price of $195.0 per contract. There were 1333 open contracts at this strike prior to today, and today 159 contract(s) were bought and sold. 
• For HUM (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>), we notice a call option trade that happens to be bearish, expiring in 64 day(s) on April 17, 2025. This event was a transfer of 65 contract(s) at a $245.00 strike. The total cost received by the writing party (or parties) was $191.7K, with a price of $2950.0 per contract. There were 141 open contracts at this strike prior to today, and today 125 contract(s) were bought and sold. 
• For HIMS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>), we notice a call option trade that happens to be bullish, expiring in 9 day(s) on February 21, 2025. This event was a transfer of 81 contract(s) at a $37.00 strike. The total cost received by the writing party (or parties) was $69.7K, with a price of $861.0 per contract. There were 1026 open contracts at this strike prior to today, and today 87 contract(s) were bought and sold. 
• For EXEL (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXEL#NASDAQ">EXEL</a>), we notice a call option trade that happens to be neutral, expiring in 9 day(s) on February 21, 2025. This event was a transfer of 18 contract(s) at a $17.00 strike. The total cost received by the writing party (or parties) was $29.5K, with a price of $1640.0 per contract. There were 98 open contracts at this strike prior to today, and today 50 contract(s) were bought and sold. 
• Regarding LLY (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), we observe a call option trade with bearish sentiment. It expires in 9 day(s) on February 21, 2025. Parties traded 5 contract(s) at a $800.00 strike. The total cost received by the writing party (or parties) was $37.5K, with a price of $7518.0 per contract. There were 843 open contracts at this strike prior to today, and today 31 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more about unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ACAD

BMRN

EXEL

RBC Capital analyst Ben Hendrix reiterates Humana (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>) with a Outperform and maintains $283 price target.

Reiteration

RBC Capital Reiterates Outperform on Humana, Maintains $283 Price Target

Cantor Fitzgerald analyst Sarah James reiterates Humana (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>) with a Neutral and maintains $290 price target.

Cantor Fitzgerald Reiterates Neutral on Humana, Maintains $290 Price Target

Morgan Stanley analyst Erin Wright maintains Humana (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>) with a Equal-Weight and lowers the price target from $301 to $285.

Morgan Stanley Maintains Equal-Weight on Humana, Lowers Price Target to $285

Press Releases

Humana Foundation Donates $250,000 to Support Disaster Recovery in the Wake of Catastrophic Flooding in Kentucky

Humana Expands Value-Based Oncology Care Through New Agreement with Thyme Care

Humana Prices $1.25 Billion Debt Offering

AM Best Assigns Issue Credit Ratings to Humana Inc.'s New Senior Unsecured Notes

Humana Completes Aggregate $1.25 Billion Debt Offering

CenterWell, Icon Health Collaborate to Transform Musculoskeletal Care for Seniors

CenterWell Bringing Convenient, Personalized Health Care to Seniors at Gladstone Walmart

AM Best Comments on Humana Inc.'s Re-Opened Senior Unsecured Notes

Legal

HUMANA ALERT: Bragar Eagel & Squire, P.C. is Investigating Humana Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Humana Inc. Announces Dates for First Quarter 2025 Earnings and June Investor Conference

Alignment Healthcare, Inc. - Common Stock

Alignment Healthcare

Clover Health Investments, Corp. - Class A Common stock

Clover Health Investments

Centene

Elevance Health

HealthEquity

Molina Healthcare

NeueHealth

Progyny

UnitedHealth Group Incorporated Common Stock (DE)

UnitedHealth Group

JP Morgan

Barclays

RBC Capital

Cantor Fitzgerald

Morgan Stanley

水曜日、Humana Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>) は、1株あたり6.96ドルの調整後EPSを報告し、これは1年前の1株あたり8.94ドルから減少しており、<a href="https://www.benzinga.com/calendars/earnings" target="_blank" rel="noreferrer noopener">5.85ドルのコンセンサス</a>を上回る結果となった。
同社は、「この業績は、私たちのメディケア・アドバンテージ事業における予想を上回る収益、加えて有利なクレーム開発と予定よりも低い運用費用（そのうちの一部は性質上のタイミングを考慮しています）が原因です」と説明した。
同社は2754億ドルの売上高を報告し、これは1年前の2675億ドルから上昇し、<a href="https://www.benzinga.com/pressreleases/24/07/b40062566/humana-reports-second-quarter-2024-financial-results-affirms-full-year-adjusted-2024-financial-gui" target="_blank" rel="noreferrer noopener">2851億ドルのコンセンサスを上回る結果となった。</a>
この売上高の増加は、1人あたりのメディケア保険料の上昇、メディケア・アドバンテージおよび州政府提供の契約の会員数増加によるもの。
「今期の売上は、予想の少し上回る結果となりました。これは、予想を上回る会員数の成長と予想をわずかに上回るメンバーリスクスコアという2つのポイントが原因です」とHumanaの経営陣は準備されたコメントで述べました。
Humanaは、2四半期末において、医療総会員数が1,630万人となり、1年前の1,713万人から減少した。
メディケア・アドバンテージの会員数は、1年前の5,270,000人から、5,620,000人に増加した。
ベネフィットレシオは、1年前の86.3％から89.0％に増加し、有利なクレーム開発と予想をわずかに上回るメンバーリスクスコアの結果となっている。この有利性は、MAのネット入院費の増加により部分的に相殺されている。
Humanaは、同四半期において有利なクレーム開発を経験し、主に入院単位コストの低下、観察入院の増加、およびクレームの回収の増加が原因。
この有利性は、四半期後半において予想を超える入院回数の増加（これは四半期の後半の期間において予想を上回る結果となった）により一部相殺されている。
見通し：Humanaは2024年までの個別のメディケア・アドバンテージの年次会員数の成長予測を75,000人から<a href="https://www.benzinga.com/news/earnings/24/04/38405775/humana-boosts-medicare-advantage-membership-2024-forecast-as-q1-earnings-performance-exceeds-expect" target="_blank" rel="noreferrer noopener">新たなターゲットの225,000人</a>に引き上げた。
同社は、コンセンサスの2024年調整後EPSが1株あたり20.31ドルに対し約16.00ドルとしている。Humanaは、2024年における保険セグメントのベネフィットレシオは約90％になると予想している。
「2025年を展望すると、私たちは持続可能な利益成長を支援するために、エンタープライズ全体での成長と生産性のさらなる実現に焦点を当てています」とHumanaは<a href="https://www.benzinga.com/news/large-cap/24/04/38413321/humana-withdraws-its-already-lowered-2025-profit-guidance" target="_blank" rel="noreferrer noopener">発表しています</a>。
株価動向：水曜日の最新チェックでHUM株は1株378.97ドルで6.32％下落している。
次の記事:
<ul>
<li><a href="https://www.benzinga.com/government/24/07/39695378/ftc-investigation-uncovers-anti-competitive-practices-by-handful-of-pharmacy-benefit-managers-includ" target="_blank" rel="noreferrer noopener">FTCの調査、CVSヘルス、UnitedHealthを含む少数の薬局福祉管理者による反競争行為を明らかに</a>。</li>
</ul>
写真：T. Schneider / シャッターストックより

Comments

Humana

ニュース

最新ニュース Humana (NYSE:HUM) 株価情報

水曜日, 7 31, 2024

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル